Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.

The present disclosure provides methods and compositions for determining the presence of microorganisms in biological fluids by processing extracellular vesicles. The fluids are treated with a composition comprising a pH buffer, a nonionic surfactant, a zwitterionic detergent, an anionic surfactant, and a reducing agent. This treatment solubilizes extracellular vesicles in the fluid, enhancing the ability of diagnostic tools to find the microorganisms. The extracellular vesicles may also be isolated before solubilizing.

The present invention provides a method for detecting and assaying Clostridium neurotoxins and identification of serotypes of botulinum neurotoxins in various food matrices and clinical samples. This method is also used for detection of BoNT inside the neuronal and epithelial cells. The method comprises detecting and assaying the presence of a Clostridium neurotoxin in a sample by: exposing the sample containing a Clostridium neurotoxin to a sample comprising a novel SNAMPXIN/SNAMP universal recombinant substrate fusion protein capable of producing a detectable FRET, following cleavage; detecting and assaying the presence of the Clostridium neurotoxin by measuring a change in the energy transfer or the luminescence signal; and detecting and assaying an electrophoretic mobility pattern of one or more cleaved protein bands or a degraded protein, using a high throughput automated system to identify the different serotypes of the Clostridium neurotoxin. SNAMPXIN/SNAMP is formed from parts of BoNT substrates SNAP-25 and VAMP.

The invention features methods panels, cartridges, and systems for detecting pathogens and for diagnosing and treating diseases, including bacteremia and sepsis.

An antibiotic susceptibility testing device of gram-negative bacteria, as well as a corresponding method, are discussed. The device has a temperature control unit (including a constant temperature chamber) and a contactless conductivity-based measurement system. Disposable glassy or PVC tubes are used as test vessels for AST. In the performance of AST assay, appropriate kind of liquid medium containing identical amount of target bacterial cells and target antibiotics at different concentrations are loaded into test tubes, following by incubation in the device at a setup temperature. The bacterial growth profile is monitored by collecting the differential values (ΔC) of conductivity of liquid medium, which depend on the proliferation of viable cells. Outcome of ΔC indicates whether the target bacterial cells are completely inhibited by the test antibiotic or not, enabling the user to judge the value of the minimal inhibitory concentration (MIC) simply.

Embodiments of the present technology include a method for testing a blood sample for sepsis. The method may include receiving a blood sample from an individual. The method may also include executing an instruction to analyze the blood sample for sepsis. In addition, the method may include measuring values of a set of characteristics in the blood sample. The set of characteristics being determined prior to measuring the values. The method may further include analyzing the values of the set of characteristics to produce a representation of a suspicion of sepsis. In addition, the method may include displaying the representation. Embodiments also include systems for testing blood sample for sepsis.

Described in certain example embodiments herein are methods of treating or preventing a Borrelia burgdorferi (B. burgdorferi) infection, a symptom thereof, or a disease, disorder or condition resulting therefrom in a subject in need thereof that include reducing or eliminating a B. burgdorferi peptidoglycan-associated protein (PAP), optionally neutrophil attracting protein A (NapA), a function thereof, activity thereof, or any combination thereof in the subject in need thereof. Also described herein are methods of diagnosing and/or prognosing B. burgdorferi infection in a subject that include detecting a B. burgdorferi PAP, optionally NapA.

The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune checkpoint inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species (Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae) and/or immunostimulatory bacterial species (Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum) in the patient's gut microbiota.

The present invention relates to detecting serum anti-FadA antibodies in test samples from a patient. Additionally, aspects of the present invention provide the basis for detection of serum anti-FadA antibody levels from test samples and correlation with various conditions of clinical relevance.

The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.